Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04762641 |
|---|---|
| Brief Title: | This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors |
| First Submitted : | January 28, 2021 |
| First Submitted that Met QC Criteria : | February 17, 2021 |
| First Posted : | February 21, 2021 |
| Last Update Submitted that Met QC Criteria : | August 23, 2023 |
| Last Update Posted : | August 25, 2023 |